04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
13:28 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Asthma Mouse and guinea pig studies identified an inhalable JAK-1 inhibitor that could help treat asthma without the side effects of systemic JAK suppression. The inhalable compound is a previously reported pyrazolopyrimidine-based JAK-1 inhibitor...
22:26 , Nov 21, 2018 |  BC Extra  |  Preclinical News

Genentech develops inhalable JAK-1 inhibitor for asthma

Genentech Inc. scientists developed an inhalable Janus kinase-1 (JAK-1) inhibitor and suggested the small molecule could help treat asthma with a better safety profile than JAK inhibitors that act systemically. The Roche (SIX:ROG; OTCQX:RHHBY) unit...
16:03 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Concert's hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) reported Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa products from Pfizer Inc. (NYSE:PFE). Twice-daily 8 mg...
00:38 , Nov 13, 2018 |  BC Extra  |  Clinical News

Concert stock falls as hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) lost $3.47 (22%) to $12.59 on Monday after reporting Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa...
02:50 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

Rethinking definitions of autoimmune disease

The autoimmune field is dialing up its search for better biomarkers as it seeks to make the next step change from the targeted therapies that overtook blanket immunosuppressants. The question is whether autoimmunity might follow...
21:45 , Oct 1, 2018 |  BC Extra  |  Company News

Pfizer COO Bourla to succeed Read as CEO

Pfizer Inc. (NYSE:PFE) named an insider, COO Albert Bourla, to succeed Ian Read as CEO on Jan. 1. During Read’s eight-year tenure, he reshaped Pfizer into a slimmer, three-part organization and helped it navigate key...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
02:23 , Jun 30, 2018 |  BioCentury  |  Product Development

Defining access potential - before it’s too late

We see it everywhere: confirmation bias. Innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. But confirmation bias is particularly problematic thanks...
19:06 , Jun 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Thrombosis Mouse studies suggest JAK inhibitors could help treat thrombosis in patients with JAK-2 mutations. In a mouse model of deep vein stenosis-induced thrombosis harboring a gain-of-function JAK-2 mutation, the JAK-1/JAK-2 inhibitor Jakafi ruxolitinib...